Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros Therapeutics

Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros
                                 Therapeutics

PR Newswire

LONDON, April 1, 2013

LONDON, April 1, 2013 /PRNewswire/ --

The healthcare sector is undergoing a major transformation after the Supreme
Court last year upheld President Obama's Affordable Care Act (ACA). While
supporters of ACA say that the reform will benefit the healthcare industry in
the long-term,critics say that reform will hurt research and development as it
will result in higher costs for the industry. For biotechnology companies such
as Amgen Inc. (NASDAQ: AMGN),Affymax Inc. (NASDAQ: AFFY),Vertex
Pharmaceuticals Inc. (NASDAQ: VRTX),Questcor Pharmaceuticals Inc. (NASDAQ:
QCOR),and Repros Therapeutics Inc. (NASDAQ: RPRX),the key will be to keep
their costs under control as they adapt to the new operating environment.
Biotechnology stocks ended mostly higher in Thursday's trading session
tracking gains in the broad market. StockCall has posted free technical
research reports on AMGN,AFFY,VRTX,QCOR,and RPRX and these can be accessed by
signing up at

http://www.stockcall.com/analysis

Amgen Inc. shares rose sharply on Thursday, touching a 52-week high. The stock
rose to a 52-week high of $102.62 before paring some of the gains to finish
the day 2.36% higher at $102.51 on above average volume of 5.51 million.
Amgen's shares gained nearly 6% in the last three sessions. The stock gained
more than 19% in the first quarter, outperforming the broad market. The
company's shares have seen a series of highs over the past two weeks, which is
a strong bullish signal. Download the free report on AMGN upon registration at

http://www.StockCall.com/AMGN040113.pdf

Shares of Affymax Inc. rallied in trading on Thursday. The stock rose to an
intra-day high of $1.42 before finishing the day 10.89% higher at $1.38 on
volume of 5.99 million. Despite Thursday's gains, Affymax's shares are down
more than 92% in 2013 so far. The stock is trading more than 95% below its
52-week high of $27.74. The company's shares are also trading significantly
below their 50-day and 200-day moving averages. AFFY technical report can be
accessed for free by signing up at

http://www.StockCall.com/AFFY040113.pdf

Vertex Pharmaceuticals Incorporated edged higher in trading on Thursday;
however, the gains were limited. The stock closed 0.26% higher at $54.97 on
above average volume of 2.36 million. The biotech company's shares gained more
than 2.30% last week. For the first quarter, the stock rose more than 31%,
compared to a gain of over 10% for the S&P 500. Its shares are now trading
close to $56 resistance level. The free report on VRTX can be downloaded by
signing up now at

http://www.StockCall.com/VRTX040113.pdf

Shares of Questcor Pharmaceuticals Inc. edged higher in last Thursday's
trading session. The stock closed 0.34% higher at $32.54 on volume of 1.15
million. Questcor's shares have gained nearly 22% so far this year, easily
outperforming the broad market. The stock is currently trading above its
50-day moving average and slightly below its 200-day moving average. Free
report on QCOR can be accessed by registering at

http://www.StockCall.com/QCOR040113.pdf

Repros Therapeutics Inc.'s shares saw a huge rally in trading on Thursday
after the company said that its testosterone treatment was successful in
late-stage study. Repros shares rose to an intra-day high of $16.39 last
Thursday before paring some of its gains to finish the day 76.34% higher at
$16.10 on above average volume of 10.05 million. The biotech company's shares
crossed above their 50-day and 200-day moving averages as a result of the
rally in the previous week's last day of trading. Register with StockCall and
download the research on RPRX for free at

http://www.StockCall.com/RPRX040113.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com , Contact
Number: +1-646-396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.